Payment overview · 2025
General Payments
$648.88
33 reported records · 8 companies
Healthcare provider profile · identity verified
Michael Dean Hartwig, MD
Allopathic & Osteopathic Physicians|Family Medicine · PERRY, OK · NPI 1457354201
Verified facts
What the public records show
CMS Open Payments records show Michael Dean Hartwig, MD received $648.88 in general payments during 2025 across 33 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 30.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Ozempic, Rybelsus, Xifaxan.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 201 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 245 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 197 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $196.14 | 30.2% | 9 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $126.41 | 19.5% | 8 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $96.76 | 14.9% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $85.36 | 13.2% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $77.91 | 12.0% | 4 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $25.12 | 3.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.26 | 3.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.92 | 3.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $648.88 | 33 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $196.14 | 9 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $126.41 | 8 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $96.76 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $61.57 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $34.65 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $26.78 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $25.12 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $23.93 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.24 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $21.26 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.92 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.34 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 197 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 201 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 69 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 127 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
201 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
245 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
69 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
127 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
197 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
27 | 27 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 441 | 69 |
| Atorvastatin Calcium | Atorvastatin Calcium | 327 | 63 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 287 | 56 |
| Gabapentin | Gabapentin | 279 | 47 |
| Amlodipine Besylate | Amlodipine Besylate | 266 | 49 |
| Losartan Potassium | Losartan Potassium | 249 | 46 |
| Jardiance | Empagliflozin | 245 | 25 |
| Metoprolol Succinate | Metoprolol Succinate | 231 | 42 |
| Farxiga | Dapagliflozin Propanediol | 201 | 24 |
| Eliquis | Apixaban | 197 | 23 |
| Lisinopril | Lisinopril | 190 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 187 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 179 | 36 |
| Famotidine | Famotidine | 178 | 32 |
| Pantoprazole Sodium | Pantoprazole Sodium | 170 | 40 |
| Simvastatin | Simvastatin | 167 | 31 |
| Donepezil Hcl | Donepezil Hcl | 154 | 20 |
| Furosemide | Furosemide | 151 | 26 |
| Potassium Chloride | Potassium Chloride | 149 | 30 |
| Allopurinol | Allopurinol | 132 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 130 | 27 |
| Carvedilol | Carvedilol | 129 | 19 |
| Ozempic | Semaglutide | 127 | 18 |
| Metformin Hcl Er | Metformin Hcl | 121 | 19 |
| Spironolactone | Spironolactone | 108 | 19 |
| Omeprazole | Omeprazole | 104 | 24 |
| Benazepril Hcl | Benazepril Hcl | 99 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 93 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 90 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 88 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 83 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 79 | 19 |
| Atenolol | Atenolol | 70 | 16 |
| Buspirone Hcl | Buspirone Hcl | 69 | suppressed |
| Mounjaro | Tirzepatide | 69 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 67 | 11 |
| Alprazolam | Alprazolam | 66 | 14 |
| Meloxicam | Meloxicam | 66 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 66 | suppressed |
| Pregabalin | Pregabalin | 63 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 62 | 15 |
| Metformin Hcl | Metformin Hcl | 62 | 11 |
| Celecoxib | Celecoxib | 61 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 60 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 60 | 13 |
| Tramadol Hcl | Tramadol Hcl | 59 | 19 |
| Sertraline Hcl | Sertraline Hcl | 58 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 56 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 53 | 47 |
| Entresto | Sacubitril/Valsartan | 53 | suppressed |
| Memantine Hcl | Memantine Hcl | 51 | suppressed |
| Ondansetron Odt | Ondansetron | 49 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 48 | suppressed |
| Rybelsus | Semaglutide | 47 | suppressed |
| Clonidine | Clonidine | 46 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 46 | suppressed |
| Levetiracetam | Levetiracetam | 45 | suppressed |
| Januvia | Sitagliptin Phosphate | 44 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 43 | 29 |
| Nystatin | Nystatin | 42 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 41 | suppressed |
| Finasteride | Finasteride | 41 | suppressed |
| Lamotrigine | Lamotrigine | 39 | suppressed |
| Mirtazapine | Mirtazapine | 39 | suppressed |
| Myrbetriq | Mirabegron | 39 | suppressed |
| Sucralfate | Sucralfate | 37 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 36 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 35 | 15 |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Sulfasalazine | Sulfasalazine | 33 | suppressed |
| Temazepam | Temazepam | 33 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 32 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 31 | suppressed |
| Irbesartan | Irbesartan | 31 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 30 | 11 |
| Digoxin | Digoxin | 30 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 30 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 25 |
| Baclofen | Baclofen | 28 | suppressed |
| Prednisone | Prednisone | 28 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 27 | 27 |
| Methylprednisolone | Methylprednisolone | 26 | 24 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 19 |
| Tradjenta | Linagliptin | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 25 | suppressed |
| Fluconazole | Fluconazole | 24 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Amantadine | Amantadine Hcl | 23 | suppressed |
| Enulose | Lactulose | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 22 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Latanoprost | Latanoprost | 21 | suppressed |
| Loperamide | Loperamide Hcl | 21 | 13 |
| Nyamyc | Nystatin | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 20 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 17 |
| Terbinafine Hcl | Terbinafine Hcl | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Azithromycin | Azithromycin | 16 | 16 |
| Colesevelam Hcl | Colesevelam Hcl | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 15 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 15 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Xifaxan | Rifaximin | 13 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Novolog | Insulin Aspart | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Timolol Maleate | Timolol Maleate | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $648.88 · 33 records | Bayer Healthcare Pharmaceuticals Inc. | AIRSUPRA, BREZTRI, Cologuard Collection Kit, ELIQUIS, FARXIGA, INSPIRE, Kerendia, MOUNJARO, Ozempic, Rybelsus, Wegovy, XIFAXAN | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error